CRIS Current Research Information System

STEFONI, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.407
AS - Asia 7.357
EU - Europa 7.247
SA - Sud America 365
Continente sconosciuto - Info sul continente non disponibili 361
AF - Africa 359
OC - Oceania 15
Totale 23.111
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.249
VN - Vietnam 2.177
NL - Olanda 2.124
SG - Singapore 1.885
CN - Cina 1.715
IT - Italia 1.104
DE - Germania 984
GB - Regno Unito 880
SE - Svezia 778
HK - Hong Kong 512
FR - Francia 301
IN - India 277
BR - Brasile 264
RU - Federazione Russa 264
UA - Ucraina 198
IE - Irlanda 169
KR - Corea 167
BD - Bangladesh 146
JP - Giappone 118
FI - Finlandia 100
TG - Togo 93
CA - Canada 92
CI - Costa d'Avorio 85
ZA - Sudafrica 78
JO - Giordania 65
EE - Estonia 57
PL - Polonia 50
HR - Croazia 49
AR - Argentina 45
NG - Nigeria 43
PH - Filippine 42
ID - Indonesia 37
BE - Belgio 36
TH - Thailandia 34
CH - Svizzera 33
SC - Seychelles 29
ES - Italia 28
AT - Austria 26
MX - Messico 26
TR - Turchia 26
TW - Taiwan 26
IQ - Iraq 24
IR - Iran 22
BG - Bulgaria 15
UZ - Uzbekistan 13
EC - Ecuador 12
SA - Arabia Saudita 12
MY - Malesia 11
CL - Cile 10
CR - Costa Rica 10
AU - Australia 9
PY - Paraguay 9
KE - Kenya 8
LB - Libano 7
PE - Perù 7
RO - Romania 7
BO - Bolivia 6
EG - Egitto 6
GR - Grecia 6
JM - Giamaica 6
LT - Lituania 6
PK - Pakistan 6
RS - Serbia 6
VE - Venezuela 6
IL - Israele 5
PS - Palestinian Territory 5
CO - Colombia 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
KZ - Kazakistan 4
NZ - Nuova Zelanda 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
HN - Honduras 3
MA - Marocco 3
MD - Moldavia 3
OM - Oman 3
PR - Porto Rico 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BW - Botswana 2
BY - Bielorussia 2
DK - Danimarca 2
ET - Etiopia 2
GT - Guatemala 2
LA - Repubblica Popolare Democratica del Laos 2
LC - Santa Lucia 2
LK - Sri Lanka 2
MN - Mongolia 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AG - Antigua e Barbuda 1
CG - Congo 1
Totale 22.731
Salva come PNG Salva come JPEG
Città #
Singapore 1.324
Eygelshoven 1.286
Ashburn 771
Southend 744
Kerkrade 666
Fairfield 625
Chandler 508
Hong Kong 477
Ho Chi Minh City 455
Frankfurt am Main 390
San Jose 369
Santa Clara 368
Hanoi 350
Hefei 338
Houston 333
Woodbridge 315
Seattle 280
Ann Arbor 270
Wilmington 258
Dong Ket 255
Beijing 232
Cambridge 221
Princeton 206
Dublin 170
Boardman 159
Bologna 159
Seoul 150
New York 146
Los Angeles 137
Milan 115
Lauterbourg 113
Jacksonville 106
Tokyo 96
Lomé 93
Berlin 88
Abidjan 85
Nanjing 81
Council Bluffs 80
Helsinki 79
Westminster 78
Buffalo 69
Padova 68
Amman 65
Da Nang 65
Rome 65
Turin 56
Jinan 55
Bremen 53
Haiphong 52
São Paulo 51
Shenyang 47
Falkenstein 43
Abeokuta 39
Chicago 39
San Diego 38
Dallas 36
Toronto 36
Changsha 34
Florence 32
Guangzhou 32
Kyiv 32
Warsaw 32
Saint Petersburg 31
Jiaxing 30
Bengaluru 29
Munich 29
Redwood City 29
Zhengzhou 28
Brussels 27
Nanchang 27
The Dalles 26
Brooklyn 25
Des Moines 25
London 25
Dearborn 24
Düsseldorf 24
Redondo Beach 24
Hyderabad 23
Nuremberg 23
Phoenix 23
Hebei 22
Shanghai 22
Amsterdam 21
Bern 21
Hangzhou 21
Tianjin 21
Modena 20
San Francisco 20
Falls Church 19
Hải Dương 19
Jakarta 19
Orem 19
Secaucus 19
Quận Bình Thạnh 18
Can Tho 17
Columbus 16
Redmond 16
Taizhou 16
Yubileyny 16
Catania 15
Totale 14.864
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.865
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 459
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 294
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 266
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 258
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 256
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 253
18 F-FDG PET in malignant lymphoma: significance of positive findings 247
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 247
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 244
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 244
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 244
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 239
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 232
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 227
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 226
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 223
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 223
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 221
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 220
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 217
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 217
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 215
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 212
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 211
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 209
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 207
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 207
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 205
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 203
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 203
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 201
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 200
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 198
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 195
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 193
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 190
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 187
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 187
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 182
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 182
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 181
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 181
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 179
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 176
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 176
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 175
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 173
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 172
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 172
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 172
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 171
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 169
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 169
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 168
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 167
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 167
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 167
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 166
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 166
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 164
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 164
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 164
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 163
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 162
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 160
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 160
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 158
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 158
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 158
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 156
Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. 154
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 154
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 152
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 151
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 151
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 149
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 148
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 147
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 145
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 144
Rituximab in primary conjunctiva lymphoma. 142
Corrigendum: Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient (Frontiers in Pediatrics, (2021), 9, (702546), 10.3389/fped.2021.702546) 140
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 138
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 135
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient 135
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 135
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 133
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 132
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 132
Clinical significance of axillary findings in patients with lymphoma during follow up. C 129
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. 129
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 126
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 126
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 125
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 124
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas 123
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 122
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 119
Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis 117
Totale 20.900
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.724
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.724
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.803 0 54 132 258 149 98 37 133 61 145 425 311
2022/20232.366 246 346 159 300 177 185 52 140 413 68 159 121
2023/2024744 62 112 57 93 59 106 48 44 26 53 33 51
2024/20253.348 136 417 259 205 502 185 309 90 62 300 164 719
2025/20269.392 584 828 565 454 748 1.690 1.655 194 1.461 542 385 286
2026/2027384 261 123 0 0 0 0 0 0 0 0 0 0
Totale 23.111